Show simple item record

dc.contributor.authorShazeeb, Mohammed Salman
dc.contributor.authorGupta, Suresh
dc.contributor.authorBogdanov, Alexei A. Jr.
dc.date2022-08-11T08:10:50.000
dc.date.accessioned2022-08-23T17:21:48Z
dc.date.available2022-08-23T17:21:48Z
dc.date.issued2013-12-01
dc.date.submitted2015-01-05
dc.identifier.citationMol Imaging Biol. 2013 Dec;15(6):675-84. doi: 10.1007/s11307-013-0653-8. <a href="http://dx.doi.org/10.1007/s11307-013-0653-8">Link to article on publisher's site</a>
dc.identifier.issn1536-1632 (Linking)
dc.identifier.doi10.1007/s11307-013-0653-8
dc.identifier.pmid23733229
dc.identifier.urihttp://hdl.handle.net/20.500.14038/48606
dc.description.abstractPURPOSE: To investigate the potential of targeted MR signal amplification strategy for imaging of EGF receptor variant III (EGFRvIII) overexpression associated with the infiltrating margin of aggressive orthotopic brain tumors. PROCEDURES: F(ab')2 fragments of humanized anti-EGFRvIII monoclonal antibody (EMD72000) were linked to deglycosylated horseradish peroxidase (HRP) and glucose oxidase (GOX). Detection of the F(ab')2 conjugate pair colocalization in vivo was enabled by a subsequent IV injection of a low molecular weight paramagnetic substrate of HRP, diTyr-GdDTPA. RESULTS: The delivery of the targeted fragments to the tumor was validated using SPECT/CT imaging of radiolabeled anti-EGFRvIII F(ab')2 conjugates. Further, by using 3 T MRI, we observed time-dependent differences in tumor signal intensity and signal retention at the endpoint depending on whether or not the animals were pre-injected with the anti-EGFRvIII F(ab')2 conjugates. CONCLUSIONS: Imaging of EGFRvIII expression in vivo was enabled by consecutive administration of targeted F(ab')2 conjugates and a paramagnetic substrate resulting in a tumor-specific receptor detection with high specificity and resolution.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23733229&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800697/
dc.subjectAnimals
dc.subjectAntibodies, Monoclonal
dc.subjectBrain Neoplasms
dc.subjectCell Line, Tumor
dc.subjectGlioma
dc.subjectHumans
dc.subjectMagnetic Resonance Imaging
dc.subjectMolecular Imaging
dc.subjectMutation
dc.subjectRats
dc.subjectRats, Nude
dc.subjectReceptor, Epidermal Growth Factor
dc.subjectInvestigative Techniques
dc.subjectNeoplasms
dc.subjectRadiology
dc.subjectTherapeutics
dc.titleMR signal amplification for imaging of the mutant EGF receptor in orthotopic human glioma model
dc.typeJournal Article
dc.source.journaltitleMolecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
dc.source.volume15
dc.source.issue6
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/radiology_pubs/92
dc.identifier.contextkey6497746
html.description.abstract<p>PURPOSE: To investigate the potential of targeted MR signal amplification strategy for imaging of EGF receptor variant III (EGFRvIII) overexpression associated with the infiltrating margin of aggressive orthotopic brain tumors.</p> <p>PROCEDURES: F(ab')2 fragments of humanized anti-EGFRvIII monoclonal antibody (EMD72000) were linked to deglycosylated horseradish peroxidase (HRP) and glucose oxidase (GOX). Detection of the F(ab')2 conjugate pair colocalization in vivo was enabled by a subsequent IV injection of a low molecular weight paramagnetic substrate of HRP, diTyr-GdDTPA.</p> <p>RESULTS: The delivery of the targeted fragments to the tumor was validated using SPECT/CT imaging of radiolabeled anti-EGFRvIII F(ab')2 conjugates. Further, by using 3 T MRI, we observed time-dependent differences in tumor signal intensity and signal retention at the endpoint depending on whether or not the animals were pre-injected with the anti-EGFRvIII F(ab')2 conjugates.</p> <p>CONCLUSIONS: Imaging of EGFRvIII expression in vivo was enabled by consecutive administration of targeted F(ab')2 conjugates and a paramagnetic substrate resulting in a tumor-specific receptor detection with high specificity and resolution.</p>
dc.identifier.submissionpathradiology_pubs/92
dc.contributor.departmentDepartment of Radiology
dc.source.pages675-84


This item appears in the following Collection(s)

Show simple item record